Clinical Trial Update: Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating 6 versus 12 months of hormonal therapy for unfavorable intermediate-risk prostate cancer, and the study is currently not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Charles LeMoyne Hospital | Conditions: Prostate Cancer (Adenocarcinoma) | Phase 3 | Status: NOT_YET_RECRUITING